- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
D. Kyle Sampson
News 7 results
In the News · Source: Medtech Insight
February 11, 2022
Kyle Sampson discusses the White House Office of Management and Budget review of the U.S. FDA’s draft harmonized Quality System Regulation
In the News · Source: Medtech Insight
In the News · Source: Bloomberg Law
In the News · Source: MedTech Insight
November 16, 2020
Kyle Sampson explains why the new U.S. Congress will work quickly to reestablish key provisions of the Affordable Care Act
Events 9 results
Webinar
September 9, 2021
14th Annual King & Spalding Medical Device Summit
Speaking Engagement
March 23, 2021
Kyle Sampson to Speak on 8th Annual Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care Products Virtual Conference
Webinar
February 23, 2021
FDA Inspections in 2021 for Drug and Device Manufacturers
Webinar
November 10, 2020
13th Annual King & Spalding Medical Device Summit
Insights 27 results
Client Alert
February 7, 2022
A Pandemic Silver Lining: FDA’s New Guidance on Using Digital Health Technologies for Clinical Investigations
Client Alert
December 30, 2021
FDA Issues Draft Guidances on Transitioning Devices from EUAs and Agency Enforcement Policies
Client Alert
August 27, 2021
FDA Rejects Bids To Market CBD-Based Dietary Supplements
Client Alert
August 6, 2021
FDA Finalizes “Intended Use” Regulations